Effect of immunostimulation with bacterial lysate on the clinical course of allergic rhinitis and the level of γδT, iNKT and cytotoxic T cells in children sensitized to grass pollen allergens: A randomized controlled trial.
allergic rhinitis
bacterial lysate
children
cytotoxic T cells
iNKT cells
γδT cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
10
2022
accepted:
03
01
2023
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
7
2
2023
Statut:
epublish
Résumé
There are many drugs for allergic rhinitis (AR), however, these drugs show variable clinical effectiveness and some side effects. Therefore, new methods of AR pharmacotherapy are being sought. The objectives of this study were to evaluate the efficacy of polyvalent mechanical bacterial lysate (PMBL) therapy in improving the clinical course of grass pollen-induced AR (seasonal AR, SAR) in children and its effect on changes in the blood level of the γδT, iNKT and cytotoxic T cell subsets. Fifty children with SAR were enrolled in this study and were randomly assigned to either the PMBL group or the placebo group. The severity of SAR symptoms was assessed using the total nasal symptom score (TNSS) and visual analogue scale (VAS). During two visits (V1, V2), peak nasal inspiratory flow (PNIF) was measured and peripheral blood was collected for immunological analyses. The study also included 2 telephone contacts (TC1, TC2). The severity of the nasal symptoms of SAR on the TNSS scale was revealed to have a significantly lower impact in the PMBL group vs the placebo group at measuring points TC1 and V2 (p = 0.01, p = 0.009, respectively). A statistically significantly lower mean severity of nasal symptoms of SAR on the VAS scale was recorded for children in the PMBL group compared to the placebo group at measuring points TC1, V2 and TC2 (p = 0.04, p = 0.04, p = 0.03, respectively). The compared groups do not show significant differences in terms of PNIF values at individual measuring points. There were no statistically significant changes in immune variables. For both groups, there was a statistically significant association between the level of Th1-like γδT cells and the severity of SAR symptoms expressed on the TNSS scale (p = 0.03) - the lower the level of Th1-like γδT cells, the higher the TNSS value. Administration of sublingual PMBL tablets during the grass pollen season proves to have a high efficacy in alleviating SAR symptoms in children sensitized to grass pollen allergens. Th1-like γδT cells may be used as potential markers for SAR severity in children. ClinicalTrials.gov, identifier (NCT04802616).
Sections du résumé
Background
There are many drugs for allergic rhinitis (AR), however, these drugs show variable clinical effectiveness and some side effects. Therefore, new methods of AR pharmacotherapy are being sought.
Objectives
The objectives of this study were to evaluate the efficacy of polyvalent mechanical bacterial lysate (PMBL) therapy in improving the clinical course of grass pollen-induced AR (seasonal AR, SAR) in children and its effect on changes in the blood level of the γδT, iNKT and cytotoxic T cell subsets.
Methods
Fifty children with SAR were enrolled in this study and were randomly assigned to either the PMBL group or the placebo group. The severity of SAR symptoms was assessed using the total nasal symptom score (TNSS) and visual analogue scale (VAS). During two visits (V1, V2), peak nasal inspiratory flow (PNIF) was measured and peripheral blood was collected for immunological analyses. The study also included 2 telephone contacts (TC1, TC2).
Results
The severity of the nasal symptoms of SAR on the TNSS scale was revealed to have a significantly lower impact in the PMBL group vs the placebo group at measuring points TC1 and V2 (p = 0.01, p = 0.009, respectively). A statistically significantly lower mean severity of nasal symptoms of SAR on the VAS scale was recorded for children in the PMBL group compared to the placebo group at measuring points TC1, V2 and TC2 (p = 0.04, p = 0.04, p = 0.03, respectively). The compared groups do not show significant differences in terms of PNIF values at individual measuring points. There were no statistically significant changes in immune variables. For both groups, there was a statistically significant association between the level of Th1-like γδT cells and the severity of SAR symptoms expressed on the TNSS scale (p = 0.03) - the lower the level of Th1-like γδT cells, the higher the TNSS value.
Conclusion
Administration of sublingual PMBL tablets during the grass pollen season proves to have a high efficacy in alleviating SAR symptoms in children sensitized to grass pollen allergens. Th1-like γδT cells may be used as potential markers for SAR severity in children.
Clinical trial registration
ClinicalTrials.gov, identifier (NCT04802616).
Identifiants
pubmed: 36733480
doi: 10.3389/fimmu.2023.1073788
pmc: PMC9887322
doi:
Substances chimiques
Allergens
0
Broncho-Vaxom
0
Banques de données
ClinicalTrials.gov
['NCT04802616']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1073788Informations de copyright
Copyright © 2023 Janeczek, Kowalska, Zarobkiewicz, Suszczyk, Mikołajczyk, Markut-Miotła, Morawska-Michalska, Bakiera, Tomczak, Kaczyńska, Emeryk, Roliński and Piotrowska-Weryszko.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Postepy Hig Med Dosw (Online). 2013 Feb 15;67:65-78
pubmed: 23475484
J Allergy Clin Immunol. 2021 Mar;147(3):1011-1019
pubmed: 32679209
Front Pharmacol. 2020 Jul 22;11:1135
pubmed: 32792957
Immunol Lett. 2013 Jan;149(1-2):62-7
pubmed: 23206888
Am J Respir Crit Care Med. 2021 Jul 1;204(1):23-33
pubmed: 33651675
Int Forum Allergy Rhinol. 2018 Feb;8(2):85-107
pubmed: 29438600
Front Immunol. 2018 Jun 20;9:1393
pubmed: 29973936
Nutrition. 2021 Sep;89:111285
pubmed: 34116395
Immunotherapy. 2021 Oct;13(15):1283-1291
pubmed: 34558985
J Allergy Clin Immunol. 2021 Oct;148(4):1081-1087.e2
pubmed: 34019913
J Allergy Clin Immunol. 2011 Apr;127(4):1064-7
pubmed: 21236476
Int J Pediatr Otorhinolaryngol. 2019 Dec;127:109674
pubmed: 31526939
Lung. 2016 Aug;194(4):687-97
pubmed: 27117798
Front Immunol. 2016 Jul 11;7:273
pubmed: 27462316
Pediatr Allergy Immunol. 2021 Nov;32(8):1813-1823
pubmed: 34097747
J Immunol. 2009 Jul 15;183(2):849-55
pubmed: 19542369
Rhinology. 2021 Oct 1;59(5):422-432
pubmed: 34463311
Pulm Pharmacol Ther. 2012 Feb;25(1):62-8
pubmed: 22155205
Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):129-38
pubmed: 17346436
N Am J Med Sci. 2011 Aug;3(8):378-83
pubmed: 22171246
Int Arch Allergy Immunol. 2021;182(9):807-818
pubmed: 33882482
Int J Occup Med Environ Health. 2019 Jun 14;32(3):281-290
pubmed: 31180070
Allergy Asthma Clin Immunol. 2021 Jan 20;17(1):10
pubmed: 33472687
Immunol Allergy Clin North Am. 2020 Nov;40(4):539-547
pubmed: 33012318
Postepy Dermatol Alergol. 2019 Aug;36(4):504-505
pubmed: 31616231
Front Pharmacol. 2012 Dec 03;3:200
pubmed: 23316161
Allergy Asthma Clin Immunol. 2015 Apr 24;11(1):16
pubmed: 25945101
J Allergy Clin Immunol. 2022 Jan;149(1):189-199
pubmed: 34126156
Lancet. 2011 Dec 17;378(9809):2112-22
pubmed: 21783242
Expert Opin Investig Drugs. 2019 Mar;28(3):267-273
pubmed: 30676119
J Immunol. 2004 Mar 1;172(5):2894-902
pubmed: 14978091
J Asthma Allergy. 2022 Jun 23;15:839-850
pubmed: 35769192
Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e107-13
pubmed: 19664013
Arch Immunol Ther Exp (Warsz). 2021 Mar 4;69(1):4
pubmed: 33661375
Otolaryngol Pol. 2018 Oct 31;72(5):1-8
pubmed: 30460909
Pharmaceutics. 2021 Feb 23;13(2):
pubmed: 33672395
Rhinology. 2019 Dec 1;57(6):451-459
pubmed: 31403136
Allergy. 2005 Jun;60(6):795-800
pubmed: 15876310
Immunity. 2002 Jun;16(6):827-38
pubmed: 12121664
Front Immunol. 2014 Jul 31;5:366
pubmed: 25132835
Ann Allergy Asthma Immunol. 2021 Aug;127(2):183-190
pubmed: 33971355
J Allergy Clin Immunol Pract. 2021 Jan;9(1):453-462
pubmed: 32858239
Int Immunopharmacol. 2019 Feb;67:35-45
pubmed: 30530167
Immunology. 2012 Jul;136(3):283-90
pubmed: 22385416
Aerobiologia (Bologna). 2011 Sep;27(3):229-238
pubmed: 21892249
Front Immunol. 2022 Jun 22;13:907149
pubmed: 35812388
Science. 2012 Apr 27;336(6080):489-93
pubmed: 22442383
Am J Respir Crit Care Med. 2003 Dec 1;168(11):1324-32
pubmed: 14644924
Eur Rev Med Pharmacol Sci. 2021 Jun;25(11):4121-4127
pubmed: 34156692
J Allergy Clin Immunol. 2020 Jan;145(1):70-80.e3
pubmed: 31627910